{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T12:27:07Z","timestamp":1787315227507,"version":"build-2736575974"},"reference-count":52,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction:<\/jats:title>\n                    <jats:p>Restless leg syndrome (RLS) pathophysiology is yet unclear. The role of iron deficiency, dysfunction of the dopaminergic system, and hypoxia are well-known mechanisms related to pathophysiology. C-type natriuretic peptide (CNP) is a neuropeptide that is released from the cerebral structures and endothelium. In current literature, serum concentrations of NT pro-CNP were correlated to concentrations of the central nervous system. In this study, we aimed to investigate the relationship between serum NT pro-CNP and other biochemical markers with RLS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods:<\/jats:title>\n                    <jats:p>A total of 45 patients with idiopathic RLS and 45 healthy subjects were included in the study and the levels of iron, ferritin, and NT pro-CNP were measured. In addition, the correlation of iron, ferritin levels, sleep disorders, and the severity of RLS with NT pro-CNP was evaluated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Serum iron level was lower in patients with RLS compared with healthy controls, but there was no significant difference between groups regarding ferritin levels. NT pro-CNP level was significantly lower in patients with RLS compared with the healthy controls. The sensitivity and specificity of NT pro-CNP were 80% and 88.9%, respectively, in the diagnosis of RLS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion:<\/jats:title>\n                    <jats:p>Our findings may support the hypoxic and dopaminergic mechanisms. It has been also reported that the CNP receptor is widely expressed in cerebral structures and the spinal cord, this also plays an important role in the development of dorsal sensorial neurons of the spinal cord. In other words, low NT pro-CNP might be related to symptoms of RLS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Serum levels of NT pro-CNP are relatively decreased in patients with RLS. A pharmacological agent, which can increase CNP, might be an effective treatment choice for symptoms of RLS and CNP might be used as an assessment tool in evaluating the efficacy of treatment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/neuroindia.ni_673_19","type":"journal-article","created":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T13:01:54Z","timestamp":1767963714000},"page":"99-104","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Restless Leg Syndrome and Association with Serum NT Pro-CNP"],"prefix":"10.4103","volume":"74","author":[{"given":"Reyhan","family":"Yuksek","sequence":"first","affiliation":[{"name":"Department of Neurology, Faculty of Medicine, Ataturk University, Erzurum, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mustafa","family":"Ceylan","sequence":"additional","affiliation":[{"name":"Department of Neurology, Faculty of Medicine, Ataturk University, Erzurum, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuray","family":"Bilge","sequence":"additional","affiliation":[{"name":"Department of Neurology, Faculty of Medicine, Ataturk University, Erzurum, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatma","family":"Simsek","sequence":"additional","affiliation":[{"name":"Department of Neurology, Faculty of Medicine, Ataturk University, Erzurum, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehmet Nuri","family":"Kocak","sequence":"additional","affiliation":[{"name":"Department of Neurology, Faculty of Medicine, Ataturk University, Erzurum, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Recep","family":"Yevgi","sequence":"additional","affiliation":[{"name":"Department of Neurology, Faculty of Medicine, Ataturk University, Erzurum, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nurinnisa","family":"Ozturk","sequence":"additional","affiliation":[{"name":"Department of Neurology, Faculty of Medicine, Ataturk University, Erzurum, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,1,9]]},"reference":[{"key":"R1-20260112","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/S1474-4422(05)70139-3","article-title":"The restless legs syndrome","volume":"4","author":"Trenkwalder","year":"2005","journal-title":"Lancet Neurol"},{"key":"R2-20260112","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.sleep.2011.11.012","article-title":"Assessment of nitric oxide, advanced oxidation protein products, malondialdehyde, and thiol levels in patients with restless legs syndrome","volume":"13","author":"Baskol","year":"2012","journal-title":"Sleep Med"},{"key":"R3-20260112","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.jsmc.2015.05.022","article-title":"Restless leg syndrome\/Willis-Ekbom disease pathophysiology","volume":"10","author":"Allen","year":"2015","journal-title":"Sleep Med Clin"},{"key":"R4-20260112","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.sleep.2016.07.028","article-title":"Iron and restless legs syndrome:Treatment, genetics and pathophysiology","volume":"31","author":"Connor","year":"2017","journal-title":"Sleep Med"},{"key":"R5-20260112","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1001\/archneur.59.3.421","article-title":"Exploring the relationship between Parkinson disease and restless legs syndrome","volume":"59","author":"Ondo","year":"2002","journal-title":"Arch Neurol"},{"key":"R6-20260112","doi-asserted-by":"crossref","first-page":"259","DOI":"10.5664\/jcsm.4540","article-title":"Sleep disorders in chronic obstructive pulmonary disease:Etiology, impact, and management","volume":"11","author":"Budhiraja","year":"2015","journal-title":"J Clin Sleep Med"},{"key":"R7-20260112","doi-asserted-by":"crossref","first-page":"71499","DOI":"10.1371\/journal.pone.0071499","article-title":"Diseases in patients coming to a sleep center with symptoms related to restless legs syndrome","volume":"8","author":"Lin","year":"2013","journal-title":"PLoS One"},{"key":"R8-20260112","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1007\/s10157-011-0485-2","article-title":"Effect of the antiplatelet agent cilostazol on endovascular inflammatory biochemical parameters and the clinical symptoms of peripheral artery disease and restless legs syndrome in hemodialysis patients","volume":"15","author":"Shiohira","year":"2011","journal-title":"Clin Exp Nephrol"},{"key":"R9-20260112","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1111\/j.1468-1331.2011.03397.x","article-title":"Hypoxia-inducible factor pathway activation in restless legs syndrome patients","volume":"18","author":"Patton","year":"2011","journal-title":"Eur J Neurol"},{"key":"R10-20260112","doi-asserted-by":"crossref","first-page":"16847","DOI":"10.1073\/pnas.0906571106","article-title":"C-type natriuretic peptide (CNP) is a bifurcation factor for sensory neurons","volume":"106","author":"Schmidt","year":"2009","journal-title":"Proc Natl Acad Sci"},{"key":"R11-20260112","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1210\/er.2005-0014","article-title":"Natriuretic peptides, their receptors, and cyclic guanosine monophosphate-dependent signaling functions","volume":"27","author":"Potter","year":"2005","journal-title":"Endocr Rev"},{"key":"R12-20260112","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1210\/endo-129-2-1104","article-title":"C-type natriuretic peptide (CNP) in rats and humans","volume":"129","author":"Komatsu","year":"1991","journal-title":"Endocrinology"},{"key":"R13-20260112","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1002\/(SICI)1096-9861(19960527)369:2<165::AID-CNE1>3.0.CO;2-1","article-title":"Localization of natriuretic peptide-activated guanylate cyclase mRNAs in the rat brain","volume":"369","author":"Herman","year":"1996","journal-title":"J Comp Neurol"},{"key":"R14-20260112","doi-asserted-by":"crossref","first-page":"25847","DOI":"10.1074\/jbc.M301223200","article-title":"Furin-mediated processing of Pro-C-type natriuretic peptide","volume":"278","author":"Wu","year":"2003","journal-title":"J Biol Chem"},{"key":"R15-20260112","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1007\/s10072-018-3562-4","article-title":"Serum NT-pro CNP levels in epileptic seizure, psychogenic non-epileptic seizure, and healthy subjects","volume":"39","author":"Ceylan","year":"2018","journal-title":"Neurol Sci"},{"key":"R16-20260112","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.parkreldis.2017.06.019","article-title":"Central and systemic C-type natriuretic peptide are both reduced in Parkinson's disease","volume":"43","author":"Woodward","year":"2017","journal-title":"Parkinsonism Relat Disord"},{"key":"R17-20260112","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/j.sleep.2014.03.025","article-title":"Restless legs syndrome\/Willis\u2013Ekbom disease diagnostic criteria:Updated International Restless Legs Syndrome Study Group (IRLSSG) consensus criteria\u2013history, rationale, description, and significance","volume":"15","author":"Allen","year":"2014","journal-title":"Sleep Med"},{"key":"R18-20260112","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.sleep.2004.03.006","article-title":"Impact, diagnosis and treatment of restless legs syndrome in a primary care population:The REST primary care study","volume":"5","author":"Hening","year":"2004","journal-title":"Sleep Med"},{"key":"R19-20260112","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1002\/mds.22274","article-title":"Prevalence of restless legs syndrome in a rural community in Japan","volume":"23","author":"Nomura","year":"2008","journal-title":"Mov Disord"},{"key":"R20-20260112","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1002\/mds.20922","article-title":"Restless legs syndrome:Epidemiological and clinicogenetic study in a South Tyrolean population isolate","volume":"21","author":"Vogl","year":"2006","journal-title":"Mov Disord"},{"key":"R21-20260112","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1212\/01.WNL.0000096173.91554.B7","article-title":"Unexpectedly low prevalence and unusual characteristics of RLS in Mersin, Turkey","volume":"61","author":"Sevim","year":"2003","journal-title":"Neurology"},{"key":"R22-20260112","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1378\/chest.129.1.76","article-title":"Prevalence and correlates of restless legs syndrome:Results from the 2005 National Sleep Foundation Poll","volume":"129","author":"Phillips","year":"2006","journal-title":"Chest"},{"key":"R23-20260112","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1002\/mds.870120111","article-title":"Clinical, polysomnographic, and genetic characteristics of restless legs syndrome:A study of 133 patients diagnosed with new standard criteria","volume":"12","author":"Montplaisir","year":"1997","journal-title":"Mov Disord"},{"key":"R24-20260112","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1212\/01.wnl.0000168910.48309.4a","article-title":"Epidemiology of restless legs syndrome in French adults A nationwide survey:The INSTANT Study","volume":"65","author":"Tison","year":"2005","journal-title":"Neurology"},{"key":"R25-20260112","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1590\/S1516-31802010000300008","article-title":"Restless legs syndrome:Literature review","volume":"128","author":"Symvoulakis","year":"2010","journal-title":"Sao Paulo Med J"},{"key":"R26-20260112","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/j.sleep.2010.07.007","article-title":"Restless legs syndrome:Understanding its consequences and the need for better treatment","volume":"11","author":"Earley","year":"2010","journal-title":"Sleep Med"},{"key":"R27-20260112","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/S1474-4422(14)70117-6","article-title":"The role of iron in brain ageing and neurodegenerative disorders","volume":"13","author":"Ward","year":"2014","journal-title":"Lancet Neurol"},{"key":"R28-20260112","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.sleep.2016.06.021","article-title":"Clinical efficacy of ferric carboxymaltose treatment in patients with restless legs syndrome","volume":"25","author":"Cho","year":"2016","journal-title":"Sleep Med"},{"key":"R29-20260112","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1016\/j.sleep.2011.06.009","article-title":"Clinical efficacy and safety of IV ferric carboxymaltose (FCM) treatment of RLS:A multi-centred, placebo-controlled preliminary clinical trial","volume":"12","author":"Allen","year":"2011","journal-title":"Sleep Med"},{"key":"R30-20260112","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1002\/ajh.23397","article-title":"The prevalence and impact of restless legs syndrome on patients with iron deficiency anemia","volume":"88","author":"Allen","year":"2013","journal-title":"Am J Hematol"},{"key":"R31-20260112","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1002\/mds.27287","article-title":"Association between serum hepcidin level and restless legs syndrome","volume":"33","author":"Dauvilliers","year":"2018","journal-title":"Mov Disord"},{"key":"R32-20260112","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1093\/sleep\/34.3.341","article-title":"The dopamine transporter is decreased in the striatum of subjects with restless legs syndrome","volume":"34","author":"Earley","year":"2011","journal-title":"Sleep"},{"key":"R33-20260112","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1016\/S1474-4422(18)30311-9","article-title":"Comorbidities, treatment, and pathophysiology in restless legs syndrome","volume":"17","author":"Trenkwalder","year":"2018","journal-title":"Lancet Neurol"},{"key":"R34-20260112","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1124\/mol.107.036418","article-title":"Inhibition of hypoxia-induced increase of blood-brain barrier permeability by YC-1 through the antagonism of HIF-1a accumulation and VEGF expression","volume":"72","author":"Yeh","year":"2007","journal-title":"Mol Pharmacol"},{"key":"R35-20260112","doi-asserted-by":"crossref","first-page":"e109636","DOI":"10.1371\/journal.pone.0109636","article-title":"Characterization of A11 neurons projecting to the spinal cord of mice","volume":"9","author":"Koblinger","year":"2014","journal-title":"PLoS One"},{"key":"R36-20260112","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s10072-007-0737-9","article-title":"Aetiopathogenesis of restless legs syndrome","volume":"28","author":"Zucconi","year":"2007","journal-title":"Neurol Sci"},{"key":"R37-20260112","first-page":"1318","article-title":"Presence of C-type natriuretic peptide in cultured human endothelial cells and plasma","volume":"263","author":"Stingo","year":"1992","journal-title":"Am J Physiol"},{"key":"R38-20260112","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1002\/dneu.22078","article-title":"CNP\/cGMP signaling regulates axon branching and growth by modulating microtubule polymerization","volume":"73","author":"Xia","year":"2013","journal-title":"Dev Neurobiol"},{"key":"R39-20260112","doi-asserted-by":"crossref","first-page":"18016","DOI":"10.1073\/pnas.0906880106","article-title":"Regulation of axonal development by natriuretic peptide hormones","volume":"106","author":"Zhao","year":"2009","journal-title":"Proc Natl Acad Sci"},{"key":"R40-20260112","doi-asserted-by":"crossref","first-page":"23060","DOI":"10.1016\/S0021-9258(18)54463-X","article-title":"Extracellular domain-IgG fusion proteins for three human natriuretic peptide receptors. Hormone pharmacology and application to solid phase screening of synthetic peptide antisera","volume":"266","author":"Bennett","year":"1991","journal-title":"J Biol Chem"},{"key":"R41-20260112","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1126\/science.1672777","article-title":"Selective activation of the B natriuretic peptide receptor by C-type natriuretic peptide (CNP)","volume":"252","author":"Koller","year":"1991","journal-title":"Science"},{"key":"R42-20260112","doi-asserted-by":"crossref","first-page":"4080","DOI":"10.2174\/138161210794519237","article-title":"C-type natriuretic peptide (CNP):Cardiovascular roles and potential as a therapeutic target","volume":"16","author":"Lumsden","year":"2010","journal-title":"Curr Pharm Des"},{"key":"R43-20260112","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1210\/endo.130.1.1309330","article-title":"Receptor selectivity of natriuretic peptide family, atrial natriuretic peptide, brain natriuretic peptide, and C-type natriuretic peptide","volume":"130","author":"Suga","year":"1992","journal-title":"Endocrinology"},{"key":"R44-20260112","doi-asserted-by":"crossref","first-page":"6186","DOI":"10.1523\/JNEUROSCI.5857-08.2009","article-title":"Neuronal PPARg deficiency increases susceptibility to brain damage after cerebral ischemia","volume":"29","author":"Zhao","year":"2009","journal-title":"J Neurosci"},{"key":"R45-20260112","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1523\/JNEUROSCI.3770-08.2009","article-title":"Regulate axon branching by the cyclic GMP pathway via inhibition of glycogen synthase kinase 3 in dorsal root ganglion sensory neurons","volume":"29","author":"Zhao","year":"2009","journal-title":"J Neurosci"},{"key":"R46-20260112","doi-asserted-by":"crossref","first-page":"5520","DOI":"10.1210\/en.2009-0490","article-title":"Expression of guanylyl cyclase (GC)-A and GC-B during brain development:Evidence for a role of GC-B in perinatal neurogenesis","volume":"150","author":"Muller","year":"2009","journal-title":"Endocrinology"},{"key":"R47-20260112","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1002\/mds.23241","article-title":"Prevalence and clinical profile of restless legs syndrome in Parkinson's disease","volume":"25","author":"Verbaan","year":"2010","journal-title":"Mov Disord"},{"key":"R48-20260112","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1159\/000375493","article-title":"Parkinson's disease and restless legs syndrome","volume":"73","author":"Ylikoski","year":"2015","journal-title":"Eur Neurol"},{"key":"R49-20260112","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/s00702-013-1123-9","article-title":"C-type natriuretic peptide in Parkinson's disease:Reduced secretion and response to deprenyl","volume":"121","author":"Espiner","year":"2014","journal-title":"J Neural Transm"},{"key":"R50-20260112","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1046\/j.0953-816x.2001.01791.x","article-title":"C-type natriuretic peptide (CNP) regulates cocaine-induced dopamine increase and immediate early gene expression in rat brain","volume":"14","author":"Thiriet","year":"2001","journal-title":"Eur J Neurosci"},{"key":"R51-20260112","doi-asserted-by":"crossref","first-page":"10716","DOI":"10.1523\/JNEUROSCI.1398-04.2004","article-title":"Activation of the cGMP pathway in dopaminergic structures reduces cocaine-induced EGR-1 expression and locomotor activity","volume":"24","author":"Jouvert","year":"2004","journal-title":"J Neurosci"},{"key":"R52-20260112","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1017\/S1461145712001630","article-title":"Cocaine self-administration by rats is inhibited by cyclic GMP-elevating agents:Involvement of epigenetic markers","volume":"16","author":"Deschatrettes","year":"2013","journal-title":"Int J Neuropsychopharmacol"}],"container-title":["Neurology India"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/neuroindia.NI_673_19","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T19:03:47Z","timestamp":1786647827000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/neuroindia.NI_673_19"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":52,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.4103\/neuroindia.ni_673_19","relation":{},"ISSN":["0028-3886","1998-4022"],"issn-type":[{"value":"0028-3886","type":"print"},{"value":"1998-4022","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"2019-08-12","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-09-27","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}